Mostrar el registro sencillo del ítem

dc.contributor.authorMangia, A.
dc.contributor.authorMilligan, S.
dc.contributor.authorKhalili, M.
dc.contributor.authorFagiuoli, S.
dc.contributor.authorShafran, S. D.
dc.contributor.authorCarrat, F.
dc.contributor.authorOuzan, D.
dc.contributor.authorPapatheodoridis, G.
dc.contributor.authorRamji, A.
dc.contributor.authorBorgia, S. M.
dc.contributor.authorWedemeyer, H.
dc.contributor.authorLosappio, R.
dc.contributor.authorPerez-Hernandez, F.
dc.contributor.authorWick, N.
dc.contributor.authorBrown, R. S.
dc.contributor.authorLampertico, P.
dc.contributor.authorDoucette, K.
dc.contributor.authorNtalla, I.
dc.contributor.authorRamroth, H.
dc.contributor.authorMertens, M.
dc.contributor.authorVanstraelen, K.
dc.contributor.authorTurnes Vázquez, Juan 
dc.date.accessioned2022-03-23T08:54:20Z
dc.date.available2022-03-23T08:54:20Z
dc.date.issued2020
dc.identifier.issn1478-3223
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/32449966es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16360
dc.description.abstractBACKGROUND AND AIMS: Achieving sustained virological response (SVR; cure) in hepatitis C patients using a simple regimen is key to making elimination by 2030 possible. In the largest real-world analysis to date, the effectiveness of pangenotypic, panfibrotic, single-tablet, sofosbuvir/velpatasvir (SOF/VEL) once-daily for 12 weeks was assessed in 12 clinical real-world cohorts from various geographical areas, settings and treatment practices. Factors affecting risk of not achieving SVR were assessed. METHODS: Adults treated with SOF/VEL 400/100 mg, without ribavirin, were included. All HCV patients reaching Week 12 or 24 post-treatment were assessed for SVR12/24. Factors associated with not achieving SVR12/24 for virological reasons were evaluated using logistic regression analysis. RESULTS: Overall, 5552 patients were included: 13.3% treatment-experienced; 20.7% compensated cirrhotic; 30.2% genotype 1; 29.5% genotype 2; 32.9% genotype 3; 4.7% genotype 4; 3.7% HIV coinfection; 13.4% current/former intravenous drug use. Of the 5196 patients evaluated for effectiveness, 98.9% achieved SVR12/24. High SVR12/24 rates occurred in all genotypes including genotype 3 (98.3%; 1649/1677) and in those with compensated cirrhosis (97.9; 1055/1078). Only 55 patients did not achieve SVR12/24 due to a virological reason; the only factor statistically significantly associated with an increased risk of not achieving SVR12/24 was compensated cirrhosis (P = .002). Overall, 6% (332/5552) of patients did not achieve SVR12/24 for non-virological reasons (67% lost to follow-up; 26.5% early treatment discontinuation). CONCLUSIONS: In this large cohort, representative of clinical practice, a simple 12-week regimen of SOF/VEL without ribavirin resulted in high SVR12/24 rates in diverse patient populations, even among those with compensated cirrhosis.en
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshHeterocyclic Compounds*
dc.subject.meshDrug Therapy*
dc.subject.meshAdult*
dc.subject.meshHumans*
dc.subject.meshTreatment Outcome*
dc.subject.meshRibavirin*
dc.subject.meshHepacivirus*
dc.subject.meshGenotype*
dc.subject.meshCarbamates*
dc.subject.meshAntiviral Agents*
dc.titleGlobal real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohortsen
dc.typeJournal Articlees
dc.authorsophosMangia, A.;Milligan, S.;Khalili, M.;Fagiuoli, S.;Shafran, S. D.;Carrat, F.;Ouzan, D.;Papatheodoridis, G.;Ramji, A.;Borgia, S. M.;Wedemeyer, H.;Losappio, R.;Perez-Hernandez, F.;Wick, N.;Brown, R. S.;Lampertico, P.;Doucette, K.;Ntalla, I.;Ramroth, H.;Mertens, M.;Vanstraelen, K.;Turnes, J.
dc.identifier.doi10.1111/liv.14537
dc.identifier.pmid32449966
dc.identifier.sophos36601
dc.issue.number8es
dc.journal.titleLIVER INTERNATIONALes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Pontevedra e O Salnés - Complexo Hospitalario Universitario de Pontevedra::Dixestivoes
dc.page.initial1841es
dc.page.final1852es
dc.relation.publisherversionhttps://air.unimi.it/retrieve/handle/2434/776962/1598458/liv.14537.pdfes
dc.rights.accessRightsopenAccess
dc.subject.decsresultado del tratamiento*
dc.subject.decsribavirina*
dc.subject.decsantivíricos*
dc.subject.decscarbamatos*
dc.subject.decsgenotipo*
dc.subject.decsfarmacoterapia*
dc.subject.decshumanos*
dc.subject.decsadulto*
dc.subject.decsHepacivirus*
dc.subject.decscompuestos heterocíclicos*
dc.subject.keywordCHUPes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number40es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional